Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
Richard Gallagher, MD, Professor of Clinical Psychiatry at New York Medical College and also a faculty member of the Columbia University Psychoanalytic Center, discusses best practices in diagnosing…
NEW YORK (Reuters Health) – In order to minimize the risk of potential harms, erythropoiesis-stimulating agents (ESAs) in patients undergoing myelosuppressive chemotherapy should be administered at the lowest…
Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment…
Emru U. Seli, MD, Assistant Professor and Director of the Third Party Reproductive Program at Yale University, discusses fertility preservation for women who are about to undergo treatment…
NEW YORK (Reuters Health) – Results of a clinical trial of the new, long-acting neuraminidase inhibitor laninamivir octanoate show that it is not inferior to oseltamivir in treating…
Charles E. Argoff, MD, Professor of Neurology and Director of the Comprehensive Pain Center, Albany Medical Center, describes new guidelines for pain management in geriatrics. The most reasonable…
NEW YORK (Reuters Health) – Postmenopausal women treated for osteoporosis with the selective estrogen receptor modulator lasofoxifene have a reduced risk of coronary heart disease events, researchers report…
NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – Children 1 to 3 years old with influenza benefit substantially from treatment with oseltamivir when it’s given within 24 hours of symptom onset,…
